Real-Time Clinical Analysis With Glympse Bio's Dr. Caroline Loew
![20_12_BPO_BusBiotech_Social_ep47 20_12_BPO_BusBiotech_Social_ep47](https://vertassets.blob.core.windows.net/image/b6f24929/b6f24929-9c3e-4ba2-a248-e8cffd89bbc9/375_250-20_12_bpo_busbiotech_social_ep47.png)
On this episode of the Business of Biotech, we're going deep with Glympse Bio President & CEO Dr. Caroline Loew to explore the possibilities and implications of the in-vivo, bioengineered, tunable sensors the company is developing for diagnostic and prognostic purposes in protease-mediates diseases. Currently in the clinic with applications for Non-Alcoholic Steatohepatitis and other fibrotic diseases as well as Non-Small Cell Lung Cancer and other solid tumors, Glympse is unlocking an unprecedented view of near-real-time therapeutic response and therapeutic efficacy that could have big implications on the way biologics are developed, refined, and studied in the clinic.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.